Mylan Still Mulling Revance's Botox Biosimilar

Firms Are Still In Discussions Despite Passing 30 April Deadline

 
• By David Wallace
  
Girl_Botox_Injection
Revance is still waiting for a decision from Mylan despite passing a key date • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products